HIV sexual transmission in serodiscordant couples and in the community [7] [8] [9] [10] [11] . Evidence suggests that expansion of HAART programs could also contribute to decreased tuberculosis burden [12] [13] [14] [15] [16] [17] [18] [19] [20] , as HAART suppresses viral activity and promotes the restoration of the immune system, thus lowering the risk of reactivating latent tuberculosis or of emerging opportunistic infections.
Global funding to fight the HIV and tuberculosis epidemics increased dramatically in 2002 and 2003 with the launch of the Global Fund to Fight AIDS, Tuberculosis and Malaria and the US President's Emergency Plan for AIDS Relief (PEPFAR) [21] [22] [23] [24] [25] . Both programs have focused on financing and developing partnerships at the country level to strengthen and implement effective tuberculosis/HIV control programs, and to rapidly accelerate access to HAART worldwide. PEPFAR's programs rolled out quickly, and were initially focused on 15 "focus countries," 12 of which were located in sub-Saharan Africa, and together accounted for nearly 50% of the people living with HIV/AIDS worldwide, and 92% of PEPFAR's programmatic investments in the 2004 fiscal year [25] . PEPFAR's programs, complemented by the Global Fund and other financial support, consisted of providing HIV prevention, treatment, care and support services, including the target of treating 2 million people with antiretroviral drugs, which was met at the end of 2008. In the end of the 2009 fiscal year, PEPFAR had expanded its scope and supported 33 countries directly and an additional 55 countries through bilateral and regional programs [24] .
Unfortunately, there are very limited longitudinal data measuring the impact of expanded HIV control activities on the tuberculosis epidemic at the country level [26] [27] [28] . Such data would be critical to inform further steps needed to enhance the effectiveness of tuberculosis/HIV programs. We, therefore, undertook the present analysis to characterize the tuberculosis incidence and mortality rates (HIV-and non-HIV-related), before and after the launch of PEPFAR, and to compare the rate of change in tuberculosis incidence relative to HIV prevalence, over time, for a selected number of PEPFAR focus countries (those countries receiving the greatest US government investments during the study period) and of non-PEPFAR focus (or "control") countries in sub-Saharan Africa.
METHODS
Incidence and mortality data on tuberculosis (all forms) for adults and children, PLWH and PnLWH, were obtained from the World Health Organization (WHO) Global Health Atlas [1, 29] . HIV prevalence data for adults and children were obtained from the Joint United Nations Programme on HIV/ AIDS (UNAIDS), and population estimates, also stratified by HIV status, were obtained via the US Census Bureau and used to calculate incidence, prevalence, and mortality rates [30] [31] [32] . We used the population at the midperiod to calculate these rates. For all indicators and population estimates, the data were gathered from 1996 to 2007. We restricted the analyses to these years, as WHO and UNAIDS have changed the way tuberculosis mortality rates are reported since 2008 (ie, tuberculosis mortality among PLWH is no longer reported separately, and these deaths are now included into the AIDS-related mortality cases).
Based on the work by Bendavid and Bhattacharya [26] , we gathered data for 12 PEPFAR focus countries in sub-Saharan Africa and 29 control countries that received < US $ 5 million annually of direct US government HIV support during the study period with a generalized HIV epidemic in sub-Saharan Africa from 1996 to 2007. In addition, countries without epidemiologic data and those in which the HIV epidemic was not generalized were excluded. The authors defined countries as having a "generalized epidemic" by having HIV prevalence of >1% in antenatal clinics and a predominantly heterosexual mode of transmission [26] . The chosen focus countries for this study were Botswana, Cote d'Ivoire, Ethiopia, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Uganda, United Republic of Tanzania, and Zambia. The control countries for this study were Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo, Democratic Republic of Congo, Djibouti, Eritrea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Lesotho, Liberia, Madagascar, Malawi, Mali, Niger, Senegal, Sierra Leone, Somalia, Sudan, Swaziland, Togo, and Zimbabwe.
Rate ratios for tuberculosis incidence and mortality rates were calculated to compare the time periods before (1996) (1997) (1998) (1999) (2000) (2001) (2002) and after (2004-2007) PEPFAR inception, and the PLWH and PnLWH population groups. The formula for each indicator is given as follows [33] :
is the ratio of the tuberculosis incidence rates before and after the inception of PEPFAR. This measure is also called the incidence relative risk. If IRR TB PEPFAR is >1, it means that the rate after the inception of PEPFAR is higher than the rate before the inception of PEPFAR. If the IRR TB PEPFAR is <1, it means that the rate after the inception of PEPFAR is lower than the rate before the inception of PEPFAR.
•
is the ratio of the tuberculosis mortality rates before and after the inception of PEPFAR. It is also called the mortality relative risk and the interpretation is similar to that for IRR TB PEPFAR .
• IRR 
=I
HIVÀnegative TB is the ratio of the tuberculosis incidence rates of HIV-positive to HIV-negative individuals.
is the ratio of the tuberculosis mortality rates of HIV-positive to HIV-negative individuals.
Recently, Sánchez et al developed a tuberculosis/HIV indicator combining data from both diseases ðR TB=HIV Þ, which calculates the rate of change in tuberculosis incidence rate relative to the HIV prevalence rate [34] . This indicator is composed by the ratio of 2 indicators: R TB ðt 1 ; n; rÞ which measures the mean change in tuberculosis incidence ðl TB Þ relative to R HIV ðt 1 ; nÞ which measures the mean change in HIV prevalence during different time periods. In this case, t 1 represents the beginning of the observation period for HIV, n represents the duration of the HIV prevalence period of observation, and r represents the delay in the period of observation of tuberculosis incidence to account for the average time-lag for HIV-positive individuals to develop active tuberculosis ( Figure 1 ). The formula to calculate R TB=HIV is given by:
where
The sign of R TB=HIV indicates which disease is increasing or decreasing relative to the other across regions, and its magnitude indicates how fast this phenomenon is happening. This measure is quite important because it allows comparisons across regions over time. Table 1 shows how to interpret R TB=HIV based on the tuberculosis incidence and HIV prevalence estimates.
RESULTS

Overall Results
Across all countries, among PLWH, the median tuberculosis incidence rate during 
Tuberculosis in PLWH and PnLWH
The median IRR Table 2 . Countries in the 75th percentile or higher were Madagascar, Senegal, Burkina Faso, Malawi, Guinea, Eritrea, and Somalia among the control countries, and Rwanda, Kenya, and Côte d'Ivoire among the focus countries. The MRR TB HIV was 43 (Q1, Q3: 33, 51) for control countries and 40 (Q1, Q3: 32, 45) for focus countries, meaning that HIV-positive individuals in both groups of countries were at least 40 times more likely to die from tuberculosis (all forms) than HIV-negative individuals. Countries in the 75th percentile or above were Madagascar, Senegal, Burkina Faso, Guinea, Benin, Malawi, and Somalia and Gambia among the control countries, and Rwanda, Kenya, and Côte d'Ivoire among the focus countries.
Before and After Analysis
Comparing the periods before (1996-2002) and after (2004-2007) PEPFAR's implementation, we estimated that 304 494 incident cases were averted in control countries vs 519 534 averted cases in focus countries, and that 128 730 mortality cases were averted in control vs 379 432 averted cases in focus countries ( Table 3 ). The median incidence rate before and after was 295 (Q1, Q3: 132, 749) and 282 (Q1, Q3: 122, 591) cases per 100 000 population (P = .0412), respectively, for control countries, and 1139 (Q1, Q3: 978, 2383) and 842 (Q1, Q3: 690, 1859) cases per 100 000 population (P = .0269), respectively, for focus countries ( Table 3 ). The median mortality rate before and after PEPFAR's initiation in control countries was, respectively, 145 (Q1, Q3: 60, 282) and 126 (Q1, Q3: 60, 282) cases per 100 000 population (P = .0025), and 445 (Q1, Q3: 360, 497) Figure 1 . Timeline to generate rate of change in tuberculosis incidence rate relative to the human immunodeficiency virus prevalence rate with n = 1996, n = 7 years and r = 4 years.
and 342 (Q1, Q3: 239, 401) cases per 100 000 population, respectively, in focus countries (P = .0342; Table 3 ).
The estimated values for IRR TB PEPFAR and MRR TB PEPFAR are found in Table 2 . The median IRR TB PEPFAR was 0.88 (Q1, Q3: 0.80, 1.05) in control countries and 0.75 (Q1, Q3: 0.62, 0.90) in focus countries. After PEPFAR's implementation, the risk of having higher incidence rates decreased for most countries, with focus countries seeing the greatest improvement. The tuberculosis incidence rate after PEPFAR initiation was higher in Angola, Chad, Gabon, Guinea, Madagascar, Sierra Leone, Senegal, and Swaziland among control countries, and South Africa and Mozambique among focus countries. The median MRR TB PEPFAR was 0.79 (Q1, Q3: 0.69, 0.96) in control countries and 0.76 (Q1, Q3: 0.62, 0.97) in focus countries. The interpretation of the median MRR TB PEPFAR is similar, and we also observed that focus countries experienced the highest improvement in mortality rates after PEPFAR's implementation. Tuberculosis mortality rates after PEPFAR initiation were lower in most countries (75% in both groups of countries) with the exception of Chad, Djibouti, Guinea, Lesotho, Madagascar, Senegal, and Sierra Leone among control countries and Botswana, Namibia, and Mozambique among focus countries.
Tuberculosis/HIV Indicator
The median R TB=HIV was −0.043 (Q1, Q3: −0.117, −0.014; Table 4 ). In a total of 18 countries (17 [94%] control and 1 [6%] focus), the HIV epidemic is outpacing the tuberculosis epidemic, with the most disparity among the control countries being Madagascar, Senegal, Angola, Gambia, and Niger, and South Africa among focus countries. Zimbabwe was the only country in which the tuberculosis epidemic is increasing despite the decrease in HIV prevalence. In 8 countries, both epidemics are decreasing (2 [25%] control and 6 [75%] focus), with the tuberculosis epidemic decreasing at a faster pace than the HIV epidemic in Kenya, United Republic of Tanzania, Côte d'Ivoire, and Ethiopia and at a slower pace in the Congo, Uganda, Burundi, and Rwanda. In the remaining 14 countries (9 [64%] control and 5 [36%] focus), the tuberculosis epidemic is decreasing while the HIV epidemic continues to increase, with the biggest disparities among control countries being Somalia, Mali, and Chad, and among focus countries being Mozambique, Namibia, and Nigeria.
DISCUSSION
The results from this ecological study examining the potential impact of PEPFAR in sub-Saharan Africa showed the importance of epidemiological monitoring to understand the spatiotemporal synergies between the tuberculosis and HIV epidemics in this heterogeneous region. We estimated that the median IRR TB HIV was 23 for control and 20 for focus countries, meaning that PLWH in both groups of countries were at least 20 times more likely to develop tuberculosis (all forms) than PnLWH, which is consistent with WHO's STOP TB Partnership reports for the Africa region [1] . Comparing the periods before and after PEPFAR's implementation, we observed that both tuberculosis incidence and mortality rates have diminished significantly and to a higher degree in focus countries. 
The tuberculosis/HIV indicator ðR TB=HIV Þ combines data from both human immunodeficiency virus (HIV) and tuberculosis, and it calculates the rate of change in tuberculosis incidence rate relative to the HIV prevalence rate. The sign of R TB=HIV indicates which disease is increasing or decreasing relative to the other, and its magnitude indicates how fast this phenomenon is happening. Thus, the magnitude of R TB and R HIV are important as well as the sign of R TB=HIV . With these quantities, we can locate in Table 1 what is happening regarding the HIV prevalence and tuberculosis incidence. Once we group the countries according to R TB=HIV , we can compare them regarding R TB and R HIV .
Abbreviations: RHIV, rate relative to the human immunodeficiency virus prevalence rate; RTB, rate of change in tuberculosis incidence.
Using the indicator R TB=HIV to understand the dynamic between tuberculosis incidence and HIV prevalence, we demonstrated that in most focus countries the tuberculosis epidemic is slowing down despite some regions still experiencing an increase in HIV prevalence. It is important to highlight that focus countries such as Kenya, United Republic of Tanzania, Uganda, and Ethiopia are experiencing a decrease in both epidemics. However, in South Africa the tuberculosis incidence seems to be increasing at a much higher rate than the HIV prevalence. It is important to mention that in most control countries, HIV prevalence and tuberculosis incidence are still increasing.
These findings provide crucial information for our current prevention efforts, shedding light on the important interactions between the tuberculosis and HIV epidemics. It is increasingly recognized that the tuberculosis/HIV epidemic in sub-Saharan Africa has had a severe impact on both tuberculosis and HIV programs and health systems, with devastating effects for people living with HIV and tuberculosis and their communities. To assess how large-scale financial and programmatic investments have helped to lower the burden of tuberculosis and HIV in this region, epidemiological indicators such as the ones used in this paper could be of considerable value. For example, it is likely that PEPFAR's effort in the region has produced positive results, but there are still countries that have not yet experienced decreases in rates of tuberculosis, probably due to surveillance artifacts and improved case finding systems. Thus, further country-specific analyses of the possible reasons for these findings should help to delineate new public health strategies to curb both epidemics. Comparing the period after and before PEPFAR's inception, we observed that some focus countries experienced increases in both tuberculosis mortality and incidence. Whether these results were real or whether they were due to biases in the country-specific surveillance and reporting data is not clear. The reasons for these countries to not respond to PEPFAR and other agency efforts should be further investigated with more recent data. However, due to the changes in data reporting, we will need to find other means to measure these trends. It is also important to mention that in these focus countries, PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria were implemented side-by-side. Therefore, countries with a high HIV burden were more likely to increase tuberculosis services concurrently, and HAART had a great impact in decreasing the burden of most opportunistic diseases and, not at the same pace, in decreasing the burden of tuberculosis.
It has been increasingly recognized that expanded HAART coverage can play a significant role in not only decreasing HIV morbidity and mortality, but also in controlling the HIV epidemic globally [7, 9, 10, 18, 35] . It should be emphasized that in resource-limited settings, historically, individuals start HIV treatment very late, usually at very low CD4 cell counts, and are mostly suffering from some AIDS-related disease, especially HIV-associated tuberculosis. At this point, these individuals have experienced severe immune deterioration and they are very likely to experience premature morbidity and mortality without ever being able to access treatment and care for their HIV disease. Also, in resource-limited settings, a significant proportion of individuals infected with HIV disease remain undiagnosed until they present with active tuberculosis, with mortality up to 30% in some settings [36] [37] [38] [39] . Consequently, the WHO recommended the "Three I's" for HIV/tuberculosis, including proactive HIV case finding initiatives coupled with the expansion of HAART at earlier stages of HIV disease, intensified tuberculosis case finding, infection control for tuberculosis, isoniazid preventive treatment, and male circumcision coupled with behavior modification interventions [17, 40, 41] , which appear to hold great promise with respect to controlling the dual epidemic of tuberculosis and HIV in resource-limited settings. As a result, we will observe an increase in tuberculosis incidence, which may be related to increased testing. However, the tuberculosis incidence may also rise during the initial months on HAART, which in large part represents prevalent disease at baseline that was not detected by screening and was unmasked as an immune reconstitution syndrome [36] . Thus, HIV and tuberculosis case finding strategies coupled with appropriate linkage to care and support, including HIV and tuberculosis treatment, have the potential to avert preventable deaths and new tuberculosis and HIV infections [1, [37] [38] [39] [42] [43] [44] [45] [46] [47] . Patients with advanced HIV disease and concomitant active tuberculosis should start antituberculosis therapy immediately, followed by the initiation of HAART within 2 weeks. However, in a recently conducted randomized clinical trial in tuberculosis meningitis among HIV-positive patients, there was no significant difference in outcome for those initiating HAART within the first week or after 8 weeks of antituberculosis therapy [43] . Among those with earlier HIV disease and higher CD4 counts who have positive tuberculin skin test results, isoniazid preventive therapy reduces the risk of tuberculosis by 64% (95% confidence interval, 39%-78%) [44] . Depending on national guidelines, such individuals may not be eligible for antiretroviral therapy, leaving isoniazid preventive treatment as the main intervention. Recently, based on the results of a randomized clinical trial, the survival benefit for concurrent treatment of both tuberculosis and HIV was confirmed, compared to initial therapy of tuberculosis followed by deferred initiation of antiretrovirals [45] . Successful delivery of tuberculosis and HIV services, which are both integrated and decentralized, has been demonstrated in Ethiopia and Rwanda [46, 47] , and is being implemented or considered in other settings. Our and these results support the need for further investment in HIV and tuberculosis programs. However, it is unclear whether the integration of these programs will or will not efficiently achieve those in need of these life-saving therapies.
There are limitations in this study. Here we presented tuberculosis and HIV ecological data for a nonrandom set of control and focus countries, therefore limiting the generalization of our findings to other countries. Second, data for this study relied on the quality of data from the multiple sources of data in this study. Third, measures of incidence and prevalence are highly dependent on the number of individuals who undergo tuberculosis and HIV testing and the ability of programs to capture this information. Thus, caution is needed in interpreting our results, given that many individuals remain unaware of their infection status. Fourth, the analyses presented here are mostly descriptive and making causal inferences are not possible, but studies such as this are important to generate hypotheses. Fifth, some of the data on PEPFAR focus countries may be explained by the speed in which the money transfer from PEPFAR to the "ground" occurs. The uptake across regions is heterogeneous (some faster than others), and it has a direct impact on the coepidemic outcomes investigated here. Finally, we have hoped that more recent data would be available to facilitate understanding of the trends of both HIV and tuberculosis epidemics. However, since 2008, there has been a change in how tuberculosis mortality cases are reported among HIV-positive individuals, and these data are not readily available for public use.
In conclusion, our results show a general trend toward lower tuberculosis incidence rates in the African countries evaluated. PEPFAR focus countries showed a more consistent and substantial effect, highlighting the likely link between high levels of HIV investment and broader effects on related diseases such as tuberculosis. Further operational research will be needed to fully and accurately characterize the relative impact of individual activities within these programs on the tuberculosis/HIV coepidemic in the region. However, to assess the effect of different programs within PEPFAR and the Global Fund, longitudinal data at the country level and specific to these programs are urgently needed. Based on the data currently available to researchers outside these institutions, it is not possible to carry out these complex analyses. Such data will be critical to inform public policy and plan for future interventions in an attempt to accelerate the efforts to control the spread of both epidemics. Informing public health decisions or donor priorities, these findings provide evidence that aggressive rollout of combined HIV and tuberculosis case finding strategies coupled with appropriate linkage to care and support, including HIV and tuberculosis treatment, have the potential to avert a substantial number of preventable tuberculosis and AIDS deaths as well as new tuberculosis and HIV infections. These results call for an in-depth country-level evaluation of existing data to answer key questions about the role of access to earlier HAART and the Three I's for HIV/tuberculosis and other interventions on improved HIV and tuberculosis control. Furthermore, the distribution of antiretroviral drugs to those in need has been shown to be cost-effective in the long-term, and, based on PEPFAR's investments, to also promote sustainability of accountability of health systems. We are confident that future health system initiatives to simplify and increase access to HIV and tuberculosis services for people living with both diseases in resource-limited countries will, with time, become easier and more efficient to be implemented in fighting these devastating epidemics. Disclaimer. The funding sources had no role in the choice of methods, the contents or form of this work, or the decision to submit the results for publication.
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